Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

Greiner Georg, MD PhD, Michael Gurbisz, MSc, Franz Ratzinger, MD, Nadine Witzeneder, MSc, Svenja-Verena Class, Ingrid Simonitsch-Klupp, MD, Harald Esterbauer, MD PhD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, Leonhard Muellauer, MD PhD, Peter Valent, Gregor Hoermann

Blood (2018) 132 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2018-99-116492

Published: 2018

Journal Articles

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Karl J. Aichberger, MD, MSci, Susanne Herndlhofer, Hermine Agis, MD, Wolfgang R. Sperr, MD, Werner Rabitsch, MD, Harald Esterbauer, MD, PhD, Paul Knoebl, MD, Christian Sillaber, MD, Ulrich Jaeger, MD, Peter Valent, MD

Blood (2007) 110 (11): 4556.

https://doi.org/10.1182/blood.V110.11.4556.4556

Published: 2007

Journal Articles

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

Christian Schuetzinger, Harald Esterbauer, MD,PhD, Cathrin Skrabs, MD, Martin Uffmann, MD, Markus Raderer, MD, Alexander Hauswirth, MD, Alexander Gaiger, MD, Christine Mannhalter, PhD, Karin Dieckmann, MD, Oswald Wagner, MD, Ulrich Jaeger, MD

Blood (2006) 108 (11): 2060.

https://doi.org/10.1182/blood.V108.11.2060.2060

Published: 2006

Journal Articles

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

Matthias Mayerhofer, MD, Alexandra Boehm, MD, Karl J. Aichberger, MD, Harald Esterbauer, MD, PhD, Sophia Derdak, MD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 4834.

https://doi.org/10.1182/blood.V106.11.4834.4834

Published: 2005

Journal Articles

Histamine Monitoring in Patients with CML during Treatment with Imatinib: Comparison to Monitoring by Cytogenetics and BCR/ABL.

Hermine Agis, MD, Susanne Herndlhofer, Hans Semper, Hendrati Pirc-Donoewenater, PhD, Oskar Haas, MD, Christine Mannhalter, MD, Harald Esterbauer, MD, PhD, Wolfgang R. Sperr, MD, Klaus Geissler, MD, Peter Valent, MD

Blood (2005) 106 (11): 4836.

https://doi.org/10.1182/blood.V106.11.4836.4836

Published: 2005

Journal Articles

c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.

Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Stefan Florian, Maria-Theresa Krauth, MD, Martin Bilban, PhD, Harald Esterbauer, MD, PhD, Oswald Wagner, MD, Reinhard Kodym, MD, Karl Sotlar, MD, Jack B. Longley, MD, Hans-Peter Horny, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2004) 104 (11): 485.

https://doi.org/10.1182/blood.V104.11.485.485

Published: 2004

Journal Articles

Microvessel Endothelial Cells of Hematological Malignancies Harbor Disease Specific Genetic Aberrations.

Ilse Schwarzinger, MD, Markus Exner, MD, Harald Esterbauer, MD, Johannes Drach, MD, Ulrich Jaeger, MD, Andreas Chott, MD, Oswald Wagner, MD, Berthold Streubel, MD

Blood (2004) 104 (11): 544.

https://doi.org/10.1182/blood.V104.11.544.544

Published: 2004

NARROW

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Predictive Value of Clonal Peripheral Blood γTCR Rearrangement in Patients with Peripheral T-Cell Lymphoma.

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

Histamine Monitoring in Patients with CML during Treatment with Imatinib: Comparison to Monitoring by Cytogenetics and BCR/ABL.

c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells.

Microvessel Endothelial Cells of Hematological Malignancies Harbor Disease Specific Genetic Aberrations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only